Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01238952 · ClinicalTrials.gov registry record · Phase 1
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
A Phase 1 study of Advanced Solid Tumors and Metastatic Triple-Negative Breast Cancer, sponsored by Nippon Kayaku Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01238952: Completed Phase 1 study of Advanced Solid Tumors and Metastatic Triple-Negative Breast Cancer, sponsored by Nippon Kayaku Co..
NCT01238952 is a Phase 1 study of Advanced Solid Tumors and Metastatic Triple-Negative Breast Cancer that has completed, run by Nippon Kayaku Co.. The registered enrollment target is 4 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01238952, a Phase 1 study of Advanced Solid Tumors and Metastatic Triple-Negative Breast Cancer, has completed, sponsored by Nippon Kayaku Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG NK012 and carboplatin
Study Locations (1)
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
What the finished NCT01238952 record still lists
NCT01238952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which NK012 and carboplatin is the first listed.
NCT01238952 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01238952 about?
NCT01238952 is a clinical study titled "Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer". The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
What is the current status of trial NCT01238952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2010-07. Estimated completion is 2013-03.
What conditions does trial NCT01238952 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Metastatic Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT01238952?
The interventions under investigation include: NK012 and carboplatin (DRUG).
Who is sponsoring clinical trial NCT01238952?
This trial is sponsored by Nippon Kayaku Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01238952 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01238952's enrollment target sits among peer trials
4 144th of 144 higher than 1 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia